Abiraterone 250mg vs. 1000mg? Multiple studies continue to show similar efficacy and ⬇️ cost (though through @costplusdrugs @mcuban, cost has gone ⬇️ significantly…), should the lower dose be the SoC in CRPC and higher dose be used as a back-up? #OncTwitter #gusm @JCOGO_ASCO

Finally got my @NIH reply after 2.5 years: REJECTED❌ Cute timing- but my study’s already FUNDED COMPLETED & PUBLISHED in @JCOGO_ASCO Appreciate the reply - but oncology runs faster. You don’t🐢🚀 Full👇Nationwide Insights on Immunotherapy in Armenia https://t.co/vhecKpUvMB

A new global guideline on #geriatricassessment is here! Get the details and see how it can impact patient care. Read more: https://t.co/yAP3pqUiYT

Celebrating #PeerReviewWeek at #JCOGO! We're immensely grateful for our reviewers—your expertise is vital to publishing high-quality, impactful research that advances cancer care worldwide. Thank you for your essential contributions over the past year: https://t.co/yOAnI8JFML

💡New article spotlight💡 Baglien et al explore the experiences of women in SSA🌍 with #breastcancer and empowerment in our latest @JCOGO_ASCO article.

Nationwide Insights on Immunotherapy in an LMIC: Armenia’s Struggle for Equitable Cancer Care in an Out-of-Pocket System. Read the full article. https://t.co/PGKoN4o8Rg #ImmunoOnc #healthequity #healthcaredisparities

Proud to share my most impactful work yet: Our article on breast cancer epidemiology, management, and disparities in India is now published in @JCOGO_ASCO @ASCO! 🔗 https://t.co/uBp1v1TRhS #BreastCancer #India #GlobalOncology

New in @JCOGO_ASCO: Go, @EChrisDee, and colleagues share an impactful commentary on barriers to immunotherapy access for patients with cancer in Southeast Asia. https://t.co/Py4EN2rZnI 👏🏻

💡@HersheyDudipala @DrRanaMcKay and team explore disparities in #prostatecancer global trends in our latest @JCOGO_ASCO article. https://t.co/DwcOAlLcMb

Gallbladder cancer is the commonest cancer in the northern parts of India. In one of the hospital based cancer registry from Patna, it was shown that it is more common than breast cancer. @JavleMilind @Jarurat_care @JCOGO_ASCO @myESMO 21% among 66000 patients studied,

Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths. https://t.co/AIcE8LVhI3 @oncodaily @JCOGO_ASCO

💡New Article Spotlight 💡 Alkhatib and ⁦⁦@iaeaorg⁩ provide a critical update on radiotherapy resources in Central Asia. Check out this our latest @JCOGO_ASCO article. ⁦

Low-Dose Abiraterone in Metastatic Castration-Resistant Prostate Cancer. Read the full article.

Barriers to Immune Checkpoint Inhibitor Access for Patients with Cancer in Southeast Asia: Challenges and Policy Implications. Read the full article.

✔️ out this important commentary on the Impact of Banning ENDS in India ⁦@JCOGO_ASCO⁩

Multicenter case-control study from @ACTREC_TMC on link between oral health & cancer just out in @JCOGO_ASCO Decayed, Missing, Filled Teeth (DMFT) score associated with risk of buccal mucosa cancer & should be included in National oral health programs https://t.co/RhJpARfZwJ

🧵 Gender Disparities in Oncology in Latin America How are female oncologists in LATAM navigating inequity, harassment, and work-life balance? A landmark study across 🇦🇷🇨🇱🇲🇽🇵🇪 sheds light on persistent gender gaps in our field published at @JCOGO_ASCO 🔍 Let's unpack the data

📜 In @JCOGO_ASCO, we highlight strengths & challenges in access to #immunotherapy for people w #cancer in #Southeast Asia 👉 Grateful to Dr Adrian Go & team! @francesvho @erin_feliciano @IyengarPuneeth @fredtingmd @KVanLoonMD 🇹🇭🇵🇭🇮🇩🇻🇳🇰🇭🇲🇲🇲🇾🇹🇱🇧🇳🇱🇦🇸🇬 🔗 https://t.co/YL4AF3MNmH

Innovative Training to Improve Childhood Cancer Knowledge amongst Primary Healthcare Providers: Evaluating a Blended Learning Program in Kenya. Read the full article. https://t.co/gzTXuNuIQ9 #pedonc